09 December 2021 | News
Driving the global growth of Taiwan's CDMO sector as a whole
image credit- shutterstock
Taiwan-based Bora Pharmaceuticals has announced a partnership with Taishin Healthcare whereby the two parties will jointly invest up to NT$3 billion (approx. $108 million) to target forward-looking contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs), in response to the development trend that is taking place worldwide.
Bora plans to expand its footprint in the CDMO sector through the deployment of private equity funds and its existing resources.
In addition, with the partnership, the company will be able to enter the macromolecular/cell and gene therapy manufacturing space, and by doing so, significantly strengthen its international competitiveness while driving the growth of Taiwan's CDMO sector.
“Taiwan offers a relatively stable market environment alongside a number of advantages, including low costs, quality services, greater convenience for doing business and a talent pool of high-level R&D professionals, making the island an ideal locale for global contract manufacturing”, said Bobby Sheng, Chairman, Bora Pharmaceuticals.